ReviewCirculation2023
Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?
Review in Circulation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 5 syntheses or guidelines pooled it, 161 citations in OpenAlex.
- Gender-Specific Associations Between Sex Hormones and Cardiovascular Disease: A Systematic Review and Meta-Analysis.Reviews in cardiovascular medicine · 2026Pooled it
- Reproductive journey in women with congenital heart disease: a systematic review of mental health implications.BMJ open · 2026Pooled it
- Citrulline supplementation in postmenopausal women: a systematic review of vascular, muscular, and metabolic effects.BMC women's health · 2026Pooled it
- A systematic review and meta-analysis of randomized controlled trials investigated the effects of melatonin supplementation on bone mineral density, quality of life, and sleep in menopausal women.Frontiers in nutrition · 2026Pooled it
- Brazilian Guideline on Menopausal Cardiovascular Health - 2024.Arquivos brasileiros de cardiologia · 2024Guideline
- Menopausal Hormone Therapy and Cardiovascular Diseases in Women With Vasomotor Symptoms: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trials.JAMA internal medicine · 2025Trial
- Geroprotective Effects of Drugs Modulating Metabolic Pathways: Perspectives of Pharmacology in Anti-Aging Therapy.International journal of molecular sciences · 2026Review
- Review
- Influence of Cardiometabolic Status on Cardiovascular Effects of Oral Menopausal Hormone Therapy.Obstetrics and gynecology · 2026Article
- Ocular microvascular changes in hypoestrogenism: an OCT/OCTA systematic review and meta-analysis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Review
- Hormone replacement therapy and asthma in women: untangling a complex relationship.ERJ open research · 2026Article
- Panax quinquefolium saponin decreases atherosclerosis in ovariectomized ApoEChinese medicine · 2026Article
- Menopausal Hormone Therapy and Cardiovascular Risk: Current Evidence and Clinical Implications.Medical sciences (Basel, Switzerland) · 2026Review
- Association between SGLT2 inhibitor use and Fournier's gangrene after genital or perineal surgery: a retrospective cohort study.World journal of urology · 2026Article
- Dose-dependent hormone actions at estrogen receptor enhancers specify distinct molecular and biological outcomes.Science advances · 2026Article
- Acute coronary syndromes across the lifespan of women.NPJ cardiovascular health · 2026Review
- Beyond Estrogen: Distribution and Hormonal Correlates of Serum Testosterone Among Postmenopausal U.S. Women, NHANES 2011-2016 and 2021-2023.Journal of clinical medicine · 2026Article
- Special issue editorial: Menopause, andropause, and mental health.Comprehensive psychoneuroendocrinology · 2026Article
- Global, regional, and national burden of chronic respiratory diseases among perimenopausal women, 1990-2021: an analysis for the Global Burden of Disease Study 2021.Journal of thoracic disease · 2026Article
- Then and Now: What We Have Learned From the WHI.The Journal of clinical endocrinology and metabolism · 2026Review
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 1 country.
Funding
Abstract
Menopausal hormone therapy (HT) was widely used in the past, but with the publication of seminal primary and secondary prevention trials that reported an excess cardiovascular risk with combined estrogen-progestin, HT use declined significantly. However, over the past 20 years, much has been learned about the relationship between the timing of HT use with respect to age and time since menopause, HT route of administration, and cardiovascular disease risk. Four leading medical societies recommend HT for the treatment of menopausal women with bothersome menopausal symptoms. In this context, this review, led by the American College of Cardiology Cardiolovascular Disease in Women Committee, along with leading gynecologists, women's health internists, and endocrinologists, aims to provide guidance on HT use, including the selection of patients and HT formulation with a focus on caring for symptomatic women with cardiovascular disease risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.